Scarica l'app Stockscreener
82.81
1.20%
-1.01
Pre-mercato:
80.33
-2.48
-2.99%
Precedente Chiudi:
$83.82
Aprire:
$81.02
Volume 24 ore:
75,859
Relative Volume:
0.44
Capitalizzazione di mercato:
$810.47M
Reddito:
-
Utile/perdita netta:
$-4.98M
Rapporto P/E:
-62.84
EPS:
-1.3177
Flusso di cassa netto:
$-3.85M
1 W Prestazione:
-4.27%
1M Prestazione:
+5.30%
6M Prestazione:
+113.43%
1 anno Prestazione:
+122.37%
Intervallo 1D:
$79.39
$83.27
Intervallo di 1 settimana:
$79.39
$91.00
Portata 52W:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Nome
Bright Minds Biosciences Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
82.81 | 820.36M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | BTIG Research | Buy |
| 2025-05-13 | Iniziato | TD Cowen | Buy |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-01-23 | Iniziato | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Bright Minds Biosciences to Present at Upcoming Conferences - Bitget
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpWhat's Next? - MarketBeat
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials - Finviz
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.9%Here's What Happened - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
Will Bright Minds Biosciences Inc. benefit from rate cutsWeekly Trading Summary & AI Based Trade Execution Alerts - mfd.ru
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
What are Bright Minds Biosciences Inc.’s recent SEC filings showingRate Cut & Weekly Top Gainers Trade List - mfd.ru
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2%Time to Sell? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Issues Earnings Results, Beats Estimates By $0.28 EPS - MarketBeat
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss - TipRanks
Is Bright Minds Biosciences Inc. stock dividend yield sustainableJuly 2025 Trends & Free Community Supported Trade Ideas - mfd.ru
Will Bright Minds Biosciences Inc. benefit from rising consumer demandQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rally Mode: Is Bright Minds Biosciences Inc undervalued by DCF analysisJuly 2025 Technicals & AI Powered Market Entry Ideas - baoquankhu1.vn
Dow Update: Will Bright Minds Biosciences Inc. benefit from AI trendsWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
How interest rate cuts could boost Bright Minds Biosciences Inc. stockJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
What are the risks of holding Olin CorporationJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Aug Big Picture: Is SSNC stock trending bullishJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
(DRUG) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
McMillan Advises Bright Minds Bioscience on its USD$175 Million Prospectus Offering - McMillan LLP
Bright Minds Biosciences closes $175 million public offering - Investing.com
Bright Minds Biosciences Closes $175.1 Million Stock Offering - marketscreener.com
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - manilatimes.net
Star TribuneBright Minds Biosciences Announces Closing of US$175 Million Public Offering - FinancialContent
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) launches $175M equity raise for trials - Stock Titan
Bright Minds Biosciences Inc Azioni (DRUG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.90%
2.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):